We used NCATS' in-house compound collection MIPE4 which consists of nearly 2,000 antineoplastic compounds with diverse and redundant mechanisms of action (MoA), and includes approved drugs, phases I-III investigational drugs, and pre-clinical molecules. The screening of this library and all following in vitro experiments were performed with continuous tumor-cell line from a human carcinoma of the exocrine pancreas (PANC-1) that is often used as a model for this highly aggressive type of pancreatic cancer.